That is such a nice thing to say Pharminvestor. I appreciate you taking the time to be supportive. You have a nice biotech spec portfolio going! NVIV won't be considered speculative much longer with potential for product income by 2014 end of year. TNGN may not be too far behind - strangely enough. Their science is so futuristic it's hard for me to remember sometimes that human trials are here. The neo-kidney trial is one I will watch very closely, as I'm sure you will too. Amazing. If they can prevent imminent dialysis - they will be invaluable - regardless of warrant structure. The world will have never seen anything like that technology. Sci-fi level medicine is accurate description. Take care!
News 
Market Data 
Discover 
